Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LKM005
MIFTS: 34

Leukemia, T-Cell, Chronic

Categories: Blood diseases, Cancer diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases
Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Leukemia, T-Cell, Chronic

About this section

MalaCards integrated aliases for Leukemia, T-Cell, Chronic:

Name: Leukemia, T-Cell, Chronic 20 71
Chronic T-Cell Leukemia 20
Leukemia, T-Cell 71
T-Cell Leukemia 20

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Infectious diseases
Anatomical: Skin diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

UMLS 71 C0023492 C0023494
Sources

Summaries for Leukemia, T-Cell, Chronic

About this section
MalaCards based summary : Leukemia, T-Cell, Chronic, also known as chronic t-cell leukemia, is related to adult t-cell leukemia and t-cell lymphoblastic leukemia/lymphoma. The drugs Zidovudine and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include t cells, myeloid and bone marrow.

Sources

Related Diseases for Leukemia, T-Cell, Chronic

About this section

Diseases in the Adult T-Cell Leukemia family:

Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, T-Cell, Chronic

Diseases related to Leukemia, T-Cell, Chronic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 536)
# Related Disease Score Top Affiliating Genes
1 adult t-cell leukemia 12.1
2 t-cell lymphoblastic leukemia/lymphoma 11.8
3 human t-cell leukemia virus type 1 11.8
4 human t-cell leukemia virus type 2 11.5
5 t-cell adult acute lymphocytic leukemia 11.5
6 t-cell prolymphocytic leukemia 11.5
7 n syndrome 11.4
8 htlv-1 associated myelopathy/tropical spastic paraparesis 11.4
9 myelopathy, htlv-1-associated 11.3
10 tropical spastic paraparesis 11.3
11 leukemia 11.3
12 t-cell acute lymphoblastic leukemia 11.3
13 pediatric t-cell leukemia 11.3
14 human t-cell leukemia virus type 3 11.3
15 lymphoma 11.2
16 glucose transporter type 1 deficiency syndrome 11.1
17 retrovirus-associated myelopathy 11.1
18 spastic paraparesis 11.0
19 leukemia, acute lymphoblastic 10.8
20 precursor t-cell acute lymphoblastic leukemia 10.8
21 human immunodeficiency virus type 1 10.8
22 severe combined immunodeficiency 10.7
23 leukemia, chronic lymphocytic 10.7
24 mycosis fungoides 10.7
25 acquired immunodeficiency syndrome 10.7
26 peripheral t-cell lymphoma 10.6
27 cutaneous t cell lymphoma 10.6
28 lymphoproliferative syndrome 10.6
29 graft-versus-host disease 10.6
30 b-cell lymphoma 10.6
31 strongyloidiasis 10.5
32 uveitis 10.5
33 exanthem 10.5
34 splenomegaly 10.5
35 hairy cell leukemia 10.5
36 bone resorption disease 10.5
37 acute leukemia 10.5
38 lymphoma, hodgkin, classic 10.5
39 retinoblastoma 10.5
40 neutropenia 10.5
41 immune deficiency disease 10.5
42 chromosomal triplication 10.5
43 lymphoma, non-hodgkin, familial 10.4
44 stomatitis 10.4
45 hypereosinophilic syndrome 10.4
46 lymphosarcoma 10.4
47 anaplastic large cell lymphoma 10.4
48 combined immunodeficiency 10.4
49 prolymphocytic leukemia 10.4
50 acute graft versus host disease 10.4

Graphical network of the top 20 diseases related to Leukemia, T-Cell, Chronic:



Diseases related to Leukemia, T-Cell, Chronic
Sources

Symptoms & Phenotypes for Leukemia, T-Cell, Chronic

About this section
Sources

Drugs & Therapeutics for Leukemia, T-Cell, Chronic

About this section

Drugs for Leukemia, T-Cell, Chronic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zidovudine Approved Phase 4 30516-87-1 35370
2
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
3
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
4 Anti-HIV Agents Phase 4
5 interferons Phase 4
6 Interferon-alpha Phase 4
7 Interferon alpha-2 Phase 4
8 Reverse Transcriptase Inhibitors Phase 4
9 Anti-Retroviral Agents Phase 4
10 Neurotransmitter Agents Phase 4
11 Psychotropic Drugs Phase 4
12 Anticonvulsants Phase 4
13
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
14
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
15
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
16
Lenograstim Approved, Investigational Phase 3 135968-09-1
17
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
18
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
19
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
20
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
21
Aclarubicin Investigational Phase 3 57576-44-0 451415
22 Etoposide phosphate Phase 2, Phase 3
23 Adjuvants, Immunologic Phase 3
24
Liposomal doxorubicin Phase 2, Phase 3 31703
25 Antimetabolites Phase 3
26
Homoharringtonine Phase 3 285033
27
Vindesine Approved, Investigational Phase 2 53643-48-4, 59917-39-4 40839
28
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
29
alemtuzumab Approved, Investigational Phase 2 216503-57-0
30
Melphalan Approved Phase 2 148-82-3 4053 460612
31
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
32
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
33
Triamcinolone Approved, Vet_approved Phase 1, Phase 2 124-94-7 31307
34
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
35
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
36
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
37
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
38
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
39
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
40
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
41
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
42
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
43
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
44
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381 214348
45
Iron Approved Phase 2 7439-89-6 23925 29936
46
Pentetic acid Approved Phase 1, Phase 2 67-43-6
47
Edetic Acid Approved, Vet_approved Phase 1, Phase 2 60-00-4, 62-33-9 6049
48
Daunorubicin Approved Phase 2 20830-81-3 30323
49
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
50
Thiotepa Approved, Investigational Phase 2 52-24-4 5453

Interventional clinical trials:

(show top 50) (show all 137)
# Name Status NCT ID Phase Drugs
1 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
3 Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
4 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Unknown status NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
5 Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
6 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
7 A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Recruiting NCT04446130 Phase 3 Decitabine combined with HAAG Regimen
8 Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Completed NCT01378871 Phase 2 IMTOX-25
9 Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease) Completed NCT01173887 Phase 2 VCAP/AMP/VECP(mLSG15)
10 A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Completed NCT01724177 Phase 2 Lenalidomide
11 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
12 Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma Completed NCT02631746 Phase 2
13 A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma Completed NCT01274533 Phase 2 Lenalidomide
14 Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Completed NCT01626664 Phase 2 Pralatrexate;gemcitabine plus oxaliplatin;DHAP
15 Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma Completed NCT00920790 Phase 2
16 A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)
17 Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma Completed NCT00081874 Phase 1, Phase 2 RAD001
18 A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia Completed NCT00001941 Phase 1, Phase 2
19 Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
20 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
21 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
22 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
23 A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma Completed NCT00611208 Phase 2
24 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
25 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
26 Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma Completed NCT00082888 Phase 2 Tipifarnib
27 Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
28 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
29 A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
30 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
31 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
32 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
33 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
34 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
35 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
36 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
37 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
38 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
39 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
40 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
41 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
42 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
43 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
44 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
45 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
46 PHASE I/II STUDY OF TAC-EXPRESSING ADULT T-CELL LEUKEMIA (ATL) WITH YTTRIUM-90 (90Y)-RADIOLABELED HUMANIZED ANTI-TAC AND CALCIUM-DTPA Completed NCT00019227 Phase 1, Phase 2 pentetic acid calcium
47 A Phase II Trial of Belinostat as Consolidation Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Recruiting NCT02737046 Phase 2 Belinostat;Zidovudine;Interferon-Alfa-2b;Pegylated Interferon-Alfa-2b
48 A Phase I/II, Multicenter, Open-Label, Nonrandomized Study to Evaluate the Tolerability and Safety of ASTX660 and the Efficacy at the Recommended Dose of ASTX660 in Patients With Relapsed or Refractory T-Cell Lymphoma Recruiting NCT04362007 Phase 1, Phase 2 ASTX660;ASTX660;ASTX660
49 Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Malignancies Recruiting NCT04689659 Phase 2
50 A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Prednisone

Search NIH Clinical Center for Leukemia, T-Cell, Chronic

Sources

Genetic Tests for Leukemia, T-Cell, Chronic

About this section
Sources

Anatomical Context for Leukemia, T-Cell, Chronic

About this section

MalaCards organs/tissues related to Leukemia, T-Cell, Chronic:

40
T Cells, Myeloid, Bone Marrow, Skin, Endothelial, B Cells, Liver
Sources

Publications for Leukemia, T-Cell, Chronic

About this section

Articles related to Leukemia, T-Cell, Chronic:

(show top 50) (show all 8800)
# Title Authors PMID Year
1
HTLV-1 viral oncoprotein HBZ contributes to the enhancement of HAX-1 stability by impairing the ubiquitination pathway. 61
32893878 2021
2
A regulatory element in the 3'-untranslated region of CEBPA is associated with myeloid/NK/T-cell leukemia. 61
33197296 2021
3
Metachronous Wilms Tumor, Glioblastoma, and T-cell Leukemia in an Child With Constitutional Mismatch Repair Deficiency syndrome due to Novel Mutation in MSH6 (c.2590G>T). 61
31815888 2021
4
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma. 61
33301622 2021
5
Ficus pumila L. improves the prognosis of patients infected with HTLV-1, an RNA virus. 61
33573641 2021
6
Biochemical Characterization, Specificity and Inhibition Studies of HTLV-1, HTLV-2, and HTLV-3 Proteases. 61
33562087 2021
7
Novel Mutations in a Lethal Case of Lymphomatous Adult T Cell Lymphoma with Cryptic Myocardial Involvement. 61
33562071 2021
8
In Vivo Tumorigenesis, Osteolytic Sarcomas, and Tumorigenic Cell Lines from Transgenic Mice Expressing the Human T-Lymphotropic Virus Type 1 (HTLV-1) Tax Viral Oncogene. 61
33181139 2021
9
Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma. 61
33576080 2021
10
Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma. 61
33597573 2021
11
Clinicopathologic Features of Peripheral T-Cell Lymphoma in Sub-Saharan Africa. 61
33527979 2021
12
In vivo dynamics and adaptation of HTLV-1-infected clones under different clinical conditions. 61
33524072 2021
13
An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. 61
32835825 2021
14
Human T-cell leukemia virus type 1 infection among Japanese immigrants and their descendants living in Southeast Brazil: A call for preventive and control responses. 61
33544713 2021
15
Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. 61
32054656 2021
16
Overexpression of aberrant Wnt5a and its effect on acquisition of malignant phenotypes in adult T-cell leukemia/lymphoma (ATL) cells. 61
33603066 2021
17
A case of vesiculobullous adult T-cell leukemia/lymphoma with a poor prognosis. 61
33580894 2021
18
Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma. 61
33594654 2021
19
Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia/lymphoma. 61
32973330 2021
20
Loss of interleukin-10 activates innate immunity to eradicate adult T cell leukemia initiating cells. 61
33567810 2021
21
Acute Pulmonary Graft-Versus-Host Disease in a Patient with Adult T-cell Leukemia-Lymphoma Diagnosed by a Cryobiopsy. 61
33583892 2021
22
Mitogen-activated protein kinases are involved in cucurbitacin D-induced antitumor effects on adult T-cell leukemia cells. 61
32914311 2021
23
Adult T-cell Leukemia/Lymphoma with Gastrointestinal Involvement. 61
33551411 2021
24
Adult T-cell leukemia/lymphoma with pagetoid reticulosis-like skin lesions. 61
33559154 2021
25
XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. 61
33563902 2021
26
RLTPR Q575E: A novel recurrent gain-of-function mutation in patients with adult T-cell leukemia/lymphoma. 61
33098696 2021
27
In vivo antagonistic role of the Human T-Cell Leukemia Virus Type 1 regulatory proteins Tax and HBZ. 61
33471856 2021
28
Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function. 61
32203145 2021
29
Implications of human T-lymphotropic virus in pregnancy: A case report and a review of the diagnostic criteria and management proposal. 61
33363593 2021
30
Retrospective Diagnosis of Ataxia-Telangiectasia in an Adolescent Patient With a Remote History of T-Cell Leukemia. 61
31743320 2021
31
Clinicopathological features of adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells. 61
33570645 2021
32
The versatile role of exosomes in human retroviral infections: from immunopathogenesis to clinical application. 61
33451365 2021
33
Inhibitory effect and mechanism of action (MOA) of hirsutine on the proliferation of T-cell leukemia Jurkat clone E6-1 cells. 61
33604171 2021
34
A Tumor Suppressor Enhancer of PTEN in T-cell development and leukemia. 61
33458694 2021
35
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy. 61
33423163 2021
36
Decrease in naïve T cell production due to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) development. 61
33338979 2021
37
An Introduction to Virus Infections and Human Cancer. 61
33200359 2021
38
HTLV-1 Replication and Adult T Cell Leukemia Development. 61
33200368 2021
39
Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry. 61
33089366 2021
40
Discovery of a Novel Inhibitor of Human Purine Nucleoside Phosphorylase by a Simple Hydrophilic Interaction Liquid Chromatography Enzymatic Assay. 61
33405358 2021
41
Possible mechanisms underlying the association between human T-cell leukemia virus type 1 (HTLV-1) and hypertension in elderly Japanese population. 61
33514303 2021
42
A new diagnostic algorithm using biopsy specimens in adult T-cell leukemia/lymphoma: combination of RNA in situ hybridization and quantitative PCR for HTLV-1. 61
32801340 2021
43
How I treat adult T-cell leukemia/lymphoma. 61
33075812 2021
44
Correction: GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma. 61
32843726 2021
45
Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. 61
33129109 2021
46
Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma. 61
33022137 2021
47
Short-term cultured autologous peripheral blood mononuclear cells as a potential immunogen to activate Tax-specific CTL response in adult T-cell leukemia patients. 61
33410215 2021
48
Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT. 61
33496743 2021
49
Genetic profile of adult T-cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLV-1 strains. 61
33426772 2021
50
Changes in awareness and knowledge concerning mother-to-child infections among Japanese pregnant women between 2012 and 2018. 61
33406131 2021
Sources

Variations for Leukemia, T-Cell, Chronic

About this section
Sources

Expression for Leukemia, T-Cell, Chronic

About this section
Search GEO for disease gene expression data for Leukemia, T-Cell, Chronic.
Sources

Pathways for Leukemia, T-Cell, Chronic

About this section
Sources

GO Terms for Leukemia, T-Cell, Chronic

About this section
Sources

Sources for Leukemia, T-Cell, Chronic

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....